MAPT and Alzheimer disease: Tideglusib (also referred to as NP12 or NP031112) is another selective GSK3 inhibitor that reduces Tau phosphorylation, decreases Aβ deposition, inhibits plaque-associated gliosis, protects neurons in the entorhinal cortex and hippocampus against cell death, and reduces memory deficits in AD mice [176].